Comparison of the efficacy of two microsphere embolic agents for transcatheter arterial chemoembolization in hepatocellular carcinoma patients

Shao Hua Lee, Chia Ying Lin, Ya Chun Hsu, Yi Sheng Liu, Ming Tsung Chuang, Ming Ching Ou

Research output: Contribution to journalArticle

Abstract

Purpose Transarterial chemoembolization (TACE) delivers cytotoxic drugs intra-arterially and induces ischemic necrosis by arterial embolization. Embolization is achieved using a variety of agents that differ widely in particle size and range, deformation, and in vivo arterial distribution. The clinical significance of these differences has not been thoroughly characterized. The present study is to compare the efficacy of Embosphere and Embozene microspheres in TACE therapy for hepatocellular carcinoma. Materials and Methods This retrospective study includes 108 hepatocellular carcinoma (HCC) patients who received TACE/doxorubicin with Embozene (70 patients) or Embosphere (38 patients) at a single medical center. Patient outcomes, including liver function, tumor size, tumor response, and complications after treatment, were analyzed. The change in total target lesion size and tumor response was evaluated according to embolization agent and clinical characteristics. Results The postoperative glutamate oxaloacetate transaminase (mean, 194.5 vs. 147.5; p=0.032) and bilirubin (mean, 1.11 mg/dL vs. 0.73 mg/dL; p=0.016) were higher among patients treated with Embozene, the decrease in the number (55.86±25.55% vs. 41.81±38.51%, p=0.027) and size (56.37±25.91 mm vs. 43.44±37.89 mm, p=0.001) of liver tumors relative to baseline was greater in these patients than in those treated with Embosphere. These greater antitumor effects were achieved using lower doses of doxorubicin than for treatment with Embozene. Minor complications were more common among patients treated with Embosphere than with Embozene. Conclusion These results suggest that Embozene is more efficacious than Embosphere for HCC treatment using TACE/doxorubicin.

Original languageEnglish
Pages (from-to)24-30
Number of pages7
JournalCancer Research and Treatment
Volume52
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Fingerprint

Microspheres
Hepatocellular Carcinoma
Doxorubicin
Neoplasms
Oxaloacetic Acid
Liver
Therapeutics
Transaminases
Bilirubin
Particle Size
Glutamic Acid
Necrosis
Retrospective Studies
trisacryl gelatin microspheres
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{a25e788b6ee1481e968f5656d1414fcd,
title = "Comparison of the efficacy of two microsphere embolic agents for transcatheter arterial chemoembolization in hepatocellular carcinoma patients",
abstract = "Purpose Transarterial chemoembolization (TACE) delivers cytotoxic drugs intra-arterially and induces ischemic necrosis by arterial embolization. Embolization is achieved using a variety of agents that differ widely in particle size and range, deformation, and in vivo arterial distribution. The clinical significance of these differences has not been thoroughly characterized. The present study is to compare the efficacy of Embosphere and Embozene microspheres in TACE therapy for hepatocellular carcinoma. Materials and Methods This retrospective study includes 108 hepatocellular carcinoma (HCC) patients who received TACE/doxorubicin with Embozene (70 patients) or Embosphere (38 patients) at a single medical center. Patient outcomes, including liver function, tumor size, tumor response, and complications after treatment, were analyzed. The change in total target lesion size and tumor response was evaluated according to embolization agent and clinical characteristics. Results The postoperative glutamate oxaloacetate transaminase (mean, 194.5 vs. 147.5; p=0.032) and bilirubin (mean, 1.11 mg/dL vs. 0.73 mg/dL; p=0.016) were higher among patients treated with Embozene, the decrease in the number (55.86±25.55{\%} vs. 41.81±38.51{\%}, p=0.027) and size (56.37±25.91 mm vs. 43.44±37.89 mm, p=0.001) of liver tumors relative to baseline was greater in these patients than in those treated with Embosphere. These greater antitumor effects were achieved using lower doses of doxorubicin than for treatment with Embozene. Minor complications were more common among patients treated with Embosphere than with Embozene. Conclusion These results suggest that Embozene is more efficacious than Embosphere for HCC treatment using TACE/doxorubicin.",
author = "Lee, {Shao Hua} and Lin, {Chia Ying} and Hsu, {Ya Chun} and Liu, {Yi Sheng} and Chuang, {Ming Tsung} and Ou, {Ming Ching}",
year = "2020",
month = "1",
day = "1",
doi = "10.4143/crt.2019.018",
language = "English",
volume = "52",
pages = "24--30",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "1",

}

Comparison of the efficacy of two microsphere embolic agents for transcatheter arterial chemoembolization in hepatocellular carcinoma patients. / Lee, Shao Hua; Lin, Chia Ying; Hsu, Ya Chun; Liu, Yi Sheng; Chuang, Ming Tsung; Ou, Ming Ching.

In: Cancer Research and Treatment, Vol. 52, No. 1, 01.01.2020, p. 24-30.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the efficacy of two microsphere embolic agents for transcatheter arterial chemoembolization in hepatocellular carcinoma patients

AU - Lee, Shao Hua

AU - Lin, Chia Ying

AU - Hsu, Ya Chun

AU - Liu, Yi Sheng

AU - Chuang, Ming Tsung

AU - Ou, Ming Ching

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Purpose Transarterial chemoembolization (TACE) delivers cytotoxic drugs intra-arterially and induces ischemic necrosis by arterial embolization. Embolization is achieved using a variety of agents that differ widely in particle size and range, deformation, and in vivo arterial distribution. The clinical significance of these differences has not been thoroughly characterized. The present study is to compare the efficacy of Embosphere and Embozene microspheres in TACE therapy for hepatocellular carcinoma. Materials and Methods This retrospective study includes 108 hepatocellular carcinoma (HCC) patients who received TACE/doxorubicin with Embozene (70 patients) or Embosphere (38 patients) at a single medical center. Patient outcomes, including liver function, tumor size, tumor response, and complications after treatment, were analyzed. The change in total target lesion size and tumor response was evaluated according to embolization agent and clinical characteristics. Results The postoperative glutamate oxaloacetate transaminase (mean, 194.5 vs. 147.5; p=0.032) and bilirubin (mean, 1.11 mg/dL vs. 0.73 mg/dL; p=0.016) were higher among patients treated with Embozene, the decrease in the number (55.86±25.55% vs. 41.81±38.51%, p=0.027) and size (56.37±25.91 mm vs. 43.44±37.89 mm, p=0.001) of liver tumors relative to baseline was greater in these patients than in those treated with Embosphere. These greater antitumor effects were achieved using lower doses of doxorubicin than for treatment with Embozene. Minor complications were more common among patients treated with Embosphere than with Embozene. Conclusion These results suggest that Embozene is more efficacious than Embosphere for HCC treatment using TACE/doxorubicin.

AB - Purpose Transarterial chemoembolization (TACE) delivers cytotoxic drugs intra-arterially and induces ischemic necrosis by arterial embolization. Embolization is achieved using a variety of agents that differ widely in particle size and range, deformation, and in vivo arterial distribution. The clinical significance of these differences has not been thoroughly characterized. The present study is to compare the efficacy of Embosphere and Embozene microspheres in TACE therapy for hepatocellular carcinoma. Materials and Methods This retrospective study includes 108 hepatocellular carcinoma (HCC) patients who received TACE/doxorubicin with Embozene (70 patients) or Embosphere (38 patients) at a single medical center. Patient outcomes, including liver function, tumor size, tumor response, and complications after treatment, were analyzed. The change in total target lesion size and tumor response was evaluated according to embolization agent and clinical characteristics. Results The postoperative glutamate oxaloacetate transaminase (mean, 194.5 vs. 147.5; p=0.032) and bilirubin (mean, 1.11 mg/dL vs. 0.73 mg/dL; p=0.016) were higher among patients treated with Embozene, the decrease in the number (55.86±25.55% vs. 41.81±38.51%, p=0.027) and size (56.37±25.91 mm vs. 43.44±37.89 mm, p=0.001) of liver tumors relative to baseline was greater in these patients than in those treated with Embosphere. These greater antitumor effects were achieved using lower doses of doxorubicin than for treatment with Embozene. Minor complications were more common among patients treated with Embosphere than with Embozene. Conclusion These results suggest that Embozene is more efficacious than Embosphere for HCC treatment using TACE/doxorubicin.

UR - http://www.scopus.com/inward/record.url?scp=85075180912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075180912&partnerID=8YFLogxK

U2 - 10.4143/crt.2019.018

DO - 10.4143/crt.2019.018

M3 - Article

C2 - 31048665

AN - SCOPUS:85075180912

VL - 52

SP - 24

EP - 30

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -